Cell Proliferation

PG11047 Phase 1 Study in advanced cancer

PG11047 is a novel Phase I clinical candidate. PG11047 is a polyamine analogue that competes with natural polyamines and treatment with PG11047 results in alterations to the natural cascade of events involved in cell division and may be able to induce cell death in tumors. Although this mechanism is unique, it has been the focus of considerable scientific interest for several years and to date PG11047 shown anti-tumor activity in animal models along with a good safety profile.  

Progen is progressing PG11047 through early clinical development in parallel to conducting additional translational studies to determine the most promising indications for PG11047.  If successful, PG11047 has the potential to provide a first-in-class oncology product.